Formulation Development
CHIMERIC COMPOUNDS - “Dopastatins”: One Molecule Targeting Two Receptors for the Treatment of Pituitary Tumors
Heather Halem, PhD, and Michael D. Culler, PhD, believe this novel class of compounds represents a potential treatment for neuroendocrine tumors that are vulnerable to the synergistic dual activation of somatostatin and dopamine receptors.
NEXT-GENERATION TUMOR TARGETING - Leveraging the Tumor Microenvironment to Change the Standard of Care
Vishwas Paralkar, PhD, highlights a unique platform technology that represents the first technology that has successfully been used to target cancer drugs to tumor cells in animal models, while sparing healthy tissue.
FORMULATION FORUM - Rational Design of Oral Nanosuspensions for Insoluble Drugs
Jim Huang, PhD, explains how nanosuspensions are an important class of pharmaceutical dosage forms, particularly for pharmaceutical compounds with solubility and bioavailability challenges.
EXECUTIVE INTERVIEW - Adare Pharmaceuticals: A Virtual Acquisition is Possible
Ajay Damani, VP of Pharmaceutical Technologies Business Unit, Adare, and Maria Flynn, President and CEO, Orbis, discuss how both companies will benefit from the acquisition, future product development, and the challenges of a virtual acquisition.
GLOBAL REPORT - 2019 Global Drug Delivery & Formulation Report: Part 4, The Drug Delivery and Formulation Pipeline
In part 4 of this 4-part series, PharmaCircle, in collaboration with Drug Development & Delivery, analyzes the pipeline with an emphasis on clinical-stage products for which there is more product-related information.
Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-004 in Parkinson’s Disease
Seelos Therapeutics, Inc. recently announced the initiation of a preclinical study of SLS-004 in Parkinson’s disease (PD) through an all-in-one lentiviral vector targeting the synuclein…
Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase 2 Study
Atriva Therapeutics GmbH recently announced a clinical strategy to treat patients with moderate to severe COVID-19 who require hospitalization. ATR-002, an oral small molecule, has…
WindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study
WindMIL Therapeutics recently announced that the first patient has been dosed in the combination therapy portion of its Phase 2 clinical trial to assess the…
ARCA Biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy
ARCA biopharma, Inc. recently announced a new development program to evaluate AB201 (rNAPc2), a potent, selective inhibitor of tissue factor (TF), as a potential treatment…
CordenPharma & Moderna Extend Strategic Manufacturing Services Agreement
CordenPharma recently announced the signing of an amendment to their existing manufacturing agreement with Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA)…
Apellis Initiates Phase 1/2 Study of APL-9 in Patients With Severe COVID-19
Apellis Pharmaceuticals, Inc. recently announced the company has initiated a Phase 1/2 clinical study of APL-9, an investigational C3 inhibitor designed for acute interventions, in…
Wondering if Investing in a Higher Purity Excipient is Really Going to Pay Off?
Wondering if investing in a higher purity excipient is really going to pay off? Check out our video web series where we speak to 3 subject matter experts on the benefits of…..
Evonik Launches Platform of Custom Functional Excipients to Precisely Control the Release Profile of Parenteral Drug Products
Evonik recently announced the launch of the RESOMER Precise platform of custom functional polymeric excipients to allow pharmaceutical companies to control…
Junshi Biosciences & Merck Announce Collaboration to Explore Promising New Combination Treatment
Junshi Biosciences and Merck recently announced their collaboration on a clinical trial program designed to investigate the efficacy and safety of…
Thermo Fisher Scientific & CSL Enter Strategic Partnership to Provide Best-in-Class Pharma Services
Thermo Fisher Scientific Inc. and CSL Limited recently announced they have entered into a strategic partnership to help meet the growing demand for biologic therapies while also….
NOVA Thin Film Pharmaceuticals & Quality Chemical Laboratories Announce Partnership in Formation & Commencement of Soluble Thin Film Operations
NOVA Thin Film Pharmaceuticals LLC (NTFP) recently announced its formation and the commencement of its soluble thin film operations……
WEBINAR ALERT- From Diluent to Differentiator: How to Choose a Diluent System That Differentiates Your Lyophilized Product
Along with a rapidly expanding global market for innovative lyophilized biologics come increased cost and competitive pressures. Today, it is critical that….
Microfluidics Enables Reliable siRNA Drug Delivery for Inflammatory Diseases & Tumor Targeting
Researchers in the Department of Pharmacy at the Ludwig Maximilian University of Munich are using chips from Dolomite Microfluidics to reliably and consistently produce monodisperse…
Ajinomoto Bio-Pharma Services Signs Manufacturing Agreement With Humanigen for Lenzilumab, Currently in FDA-Approved Phase 3 Study for COVID-19
Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, recently announced it has entered into a manufacturing agreement with Humanigen, Inc.,…
KBP Biosciences Completes Enrollment of BLOCK CKD Phase 2b Study
KBP Biosciences recently announced it has completed patient enrollment of BLOCK CKD (Blood Pressure in Chronic Kidney Disease), its Phase 2b study of its lead…
